Article
Gastroenterology & Hepatology
George Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-Gomez, Bettina E. Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Rafael Esteban, Harry L. A. Janssen, Thomas Berg, Pietro Lampertico
Summary: In nucleos(t)ide analogue-treated Caucasian patients with chronic hepatitis B, Asian HCC risk scores offer good predictability for HCC development within 5- and 10-year periods, similar to PAGE-B. The simplicity in clinical practice of PAGE-B and mPAGE-B scores makes them advantageous, as they do not require an accurate diagnosis of cirrhosis.
Article
Gastroenterology & Hepatology
Feng Su, Kristin Berry, George N. Ioannou
Summary: This study found no difference in the risk of HCC between patients with CHB treated with ETV and TDF, supporting the current guideline recommendations that both agents are appropriate first-line options for the treatment of CHB.
Article
Gastroenterology & Hepatology
Dong Ji, Yan Chen, Jingfeng Bi, Qinghua Shang, Huabao Liu, Jia-Bo Wang, Lin Tan, Jing Wang, Yongping Chen, Qin Li, Qinghua Long, Laicheng Song, Li Jiang, Guangming Xiao, Zujiang Yu, Liang Chen, Xiaodong Wang, Da Chen, Zhiqin Li, Zheng Dong, Yongping Yang
Summary: This study demonstrates that adding a traditional Chinese medicine called Biejia-Ruangan compound to antiviral treatment can reduce the risk of liver cancer in patients with chronic hepatitis B.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
Summary: The study found that CHB patients treated with ETV and TAF have similar risk of developing HCC, suggesting that further research with larger sample sizes and longer follow-up periods is needed for validation.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Won-Mook Choi, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, W. Ray Kim, Leland J. Yee, Craig Brooks-Rooney, Tristan Curteis, Harriet Cant, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang, Young-Joo Jin, Dae Won Jun, Jin-Woo Kim, Neung Hwa Park, Cheng-Yuan Peng, Hyun Phil Shin, Woo Shin, Yao-Hsu Yang, Young-Suk Lim
Summary: This study compared the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) treatment. The results showed that patients receiving TDF had a significantly lower HCC risk, especially those with HBeAg positivity.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jonggi Choi, Chanyoung Jo, Young-Suk Lim
Summary: This study compared HCC recurrence and survival in HBV-related HCC patients treated with TDF or ETV after surgical resection, finding that TDF therapy was associated with a significantly lower risk of HCC recurrence and better overall survival.
Article
Medicine, General & Internal
Darren Jun Hao Tan, Cheng Han Ng, Phoebe Wen Lin Tay, Nicholas Syn, Mark D. Muthiah, Wen Hui Lim, Ansel Shao Pin Tang, Kai En Lim, Grace En Hui Lim, Nobuharu Tamaki, Beom Kyung Kim, Margaret Li Peng Teng, James Fung, Rohit Loomba, Mindie H. Nguyen, Daniel Q. Huang
Summary: This study conducted a reconstructed individual patient data meta-analysis to provide robust estimates for the comparative hepatocellular carcinoma (HCC) risk between patients receiving tenofovir or entecavir. The results showed that tenofovir was associated with decreased HCC incidence compared with entecavir. However, there was no significant difference in the analysis of clinical cohort studies. The mean time to HCC development was slightly longer for patients receiving tenofovir compared to those receiving entecavir in administrative database studies.
Article
Business, Finance
Anita Kopanyi-Peuker, Matthias Weber
Summary: The study examines the role of investor experience in the formation of asset price bubbles by conducting call market and learning-to-forecast experiments. Despite participant experience, sizable bubbles persist in both experiments, with findings contrasting with existing literature in the call market experiment and novel findings in the learning-to-forecast experiment.
REVIEW OF FINANCIAL STUDIES
(2021)
Article
Gastroenterology & Hepatology
Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Soo Young Park, Seung Up Kim
Summary: This study validated the predictive accuracy of several prediction scores for the early detection of hepatocellular carcinoma in Korean chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate. Older age, male sex, liver cirrhosis, and prolonged prothrombin time were independently associated with an increased risk of HCC, while a higher platelet count was associated with a decreased risk. The AASL score showed the highest predictive accuracy among the four prediction scores assessed.
JOURNAL OF VIRAL HEPATITIS
(2021)
Article
Gastroenterology & Hepatology
Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Mandy Sze-Man Lai, Jimmy Che-To Lai, Yee-Kit Tse, Lilian Yan Liang, Vicki Wing-Ki Hui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong
Summary: This study aimed to investigate the impact of changing clinical characteristics and the presence of diabetes mellitus on hepatocellular carcinoma (HCC) risk scores. The study found that the prevalence of diabetes in patients with chronic hepatitis B treated with entecavir/tenofovir increased over time. The performance of various HCC risk scores was comparable across different time periods. The scores had lower accuracy in diabetic patients compared to non-diabetic patients. The REAL-B score performed well in both diabetic and non-diabetic patients and can be considered the preferred score.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
W. Ray Kim, Laura E. Telep, Belinda Jump, Mei Lu, Heribert Ramroth, John Flaherty, Anuj Gaggar, Anand P. Chokkalingam, Stuart C. Gordon
Summary: Among chronic hepatitis B patients in the United States, treatment with TDF is associated with a significantly lower risk of hepatocellular carcinoma (HCC) compared to ETV.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Wei-Yu Kao, Elise Chia-Hui Tan, Hsin-Lun Lee, Yi-Hsiang Huang, Teh-Ia Huo, Chun-Chao Chang, Jeng-Fong Chiou, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
Summary: This study compared the prognoses of patients with HBV-related HCC after hepatectomy who received ETV or TDF treatment and found that both treatments showed similar health benefits in terms of tumor recurrence and overall survival.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Xiao-Hui Wang, Zi-Li Hu, Yi-Zhen Fu, Jing-Yu Hou, Wen-Xuan Li, Yao-Jun Zhang, Li Xu, Qun-Fang Zhou, Min-Shan Chen, Zhong-Guo Zhou
Summary: This study assessed the impact of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the prognosis of patients with hepatocellular carcinoma (HCC) related to hepatitis B virus (HBV). The results showed that TDF treatment had significantly better overall survival and better protection of liver function compared to ETV treatment, but there was no difference in the incidence of HCC recurrence between the two.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Cell Biology
Jie Yuan, Yang Peng, Fa-Bao Hao, Ya-Qin Wang, Chun-Rui Wang, Guo-Chao Zhong
Summary: The study found no significant difference in reducing HCC incidence among treatment-naive CHB patients between TDF and entecavir in both multivariable-adjusted and propensity-score-matched meta-analyses. The similarity of TDF to entecavir for HCC prevention persisted in studies with follow-up length of >= 4 years.
Article
Gastroenterology & Hepatology
Tetsuya Hosaka, Fumitaka Suzuki, Mariko Kobayashi, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
Summary: The study found that measuring HBcrAg using an ultrasensitive assay has a better potential for predicting the development of hepatocellular carcinoma in patients with chronic hepatitis B undergoing antiviral treatment.
HEPATOLOGY COMMUNICATIONS
(2022)
Letter
Gastroenterology & Hepatology
Laurens A. Van Kleef, Ibrahim Ayada, Robert J. De Knegt
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Laurens A. Van Kleef, Ibrahim Ayada, Robert J. de Knegt
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Laurens A. van Kleef, Robert J. de Knegt, Willem Pieter Brouwer
Article
Immunology
Sylvia M. Brakenhoff, Margo J. H. van Campenhout, Annemiek A. van der Eijk, Willem P. Brouwer, Florian van Bommel, Bettina E. Hansen, Thomas Berg, Harry L. A. Janssen, Robert A. de Man, Milan J. Sonneveld
Summary: The study aimed to investigate the relationship between off-treatment ALT flares and virological outcomes, as well as to explore whether serum levels of novel biomarkers at the end of treatment can predict flares. The results showed that ALT flares were associated with decreased sustained response rates, and higher levels of HBsAg, HBV RNA, and HBcrAg were associated with an increased risk of flares.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2023)
Article
Gastroenterology & Hepatology
Silvia Chang, Charlotte Hedskog, Bandita Parhy, Ross Martin, Hongmei Mo, Evguenia Maiorova, Fabien Zoulim
Summary: Antiviral nucleos(t)ide analogue therapies can inhibit HBV replication and reduce HBV DNA levels, but HBV RNA levels may remain high. HBV RNA can be used as a viral biomarker for treatment outcome and disease progression. This study characterized the sequence of extracellular HBV RNA in plasma samples of patients with chronic HBV infection, and found that it closely resembles HBV DNA sequence. Additionally, RNA splice forms, different polyA tails start positions, and HBV-human chimeric transcript were identified.
JOURNAL OF VIRAL HEPATITIS
(2023)
Article
Medicine, General & Internal
D. P. C. van der Spek, W. K. Katwaroe, L. A. van Kleef, S. Brakenhoff, R. A. de Man, R. J. de Knegt, A. J. van der Meer, M. J. Sonneveld
Summary: The characteristics of newly referred chronic hepatitis B (CHB) patients are changing, with older age, less active HBV-related liver disease, and a higher likelihood of being co-affected by metabolic dysfunction associated fatty liver disease (MAFLD). These findings provide guidance for resource allocation to address the changing characteristics of the CHB population.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Medicine, General & Internal
Sylvia M. Brakenhoff, Roos Hoekstra, Pieter Honkoop, Robert Roomer, Jan G. den Hollander, Geert Bezemer, Robert J. de Knegt, Milan J. Sonneveld, Robert A. de Man
Summary: This study evaluated the adherence to international guidelines for preventing hepatitis B reactivation among patients with chronic or resolved hepatitis B who are treated with rituximab. The results showed that many patients were not correctly screened for hepatitis B infection and antiviral prophylaxis was often not initiated. Although screening rates improved over time, they remain suboptimal. These findings could raise awareness among all medical specialties prescribing these agents.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim
Summary: Functional cure of chronic hepatitis B (CHB), achieved through hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy, is the goal of current treatment. However, the rarity of achieving this cure with current therapy highlights the need for novel approaches. The three categories of treatment include reducing viral replication, reducing antigen load, and immunotherapies. Combination therapy of nucleos(t)ide analogues and immunotherapy shows promise in reducing HBsAg levels and inducing HBsAg loss in some patients, particularly those with low baseline HBsAg levels. Monitoring during therapy using viral and immunological biomarkers is important to predict HBsAg loss and understand its mechanisms.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Physiology
Arnaud Riff, Muzhda Haem Rahimi, Marie-Charlotte Delignette, Morgane Gossez, Remy Coudereau, Solene Pantel, Teresa Antonini, Francois Villeret, Fabien Zoulim, Jean-Yves Mabrut, Jerome Dumortier, Fabienne Venet, Fanny Lebosse, Guillaume Monneret
Summary: This study found that the phenotypes of neutrophils and lymphocytes, along with the expression of immune checkpoint proteins, were altered in cirrhotic patients before and after liver transplantation. These findings highlight the potential importance of immune monitoring in cirrhotic patients during liver transplantation to better assess the risk of infection.
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Endocrinology & Metabolism
Cyrielle Caussy, Charlene Telliam, Bader Al-Nuaimi, Marianne Maynard-Muet, Jerome Dumortier, Fabien Zoulim, Emmanuel Disse, Cyrille Colin, Massimo Levrero, Philippe Moulin
Summary: A pathway-referral using transient elastography (TE) performed in diabetology and nutrition clinics significantly improves the liver fibrosis risk stratification and avoids over-referral. However, collaboration between diabetologists, nutritionists, and hepatologists is needed to avoid under-referral.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2023)
Article
Gastroenterology & Hepatology
Milan J. Sonneveld, Shao-Ming Chiu, Jun Yong Park, Sylvia M. Brakenhoff, Apichat Kaewdech, Wai-Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Piero Colombatto, Florian van Boemmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George N. Dalekos, Nicole S. Erler, Maurizia Brunetto, Heiner Wedemeyer, Markus Cornberg, Man-Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien-Hung Chen, Benjamin Maasoumy, Create Study Grp
Summary: This study investigated the association between pretreatment HBV DNA levels and outcomes after therapy cessation in patients with chronic hepatitis B. It was found that lower pretreatment HBV DNA levels were associated with a lower risk of clinical relapse and a higher chance of HBsAg loss after cessation of NUC therapy. These findings can help select patients for treatment withdrawal and guide intensity of off-treatment monitoring.
Article
Gastroenterology & Hepatology
Francois Vileret, Fanny Lebosse, Sylvie Radenne, Didier Samuel, Bruno Roche, Jean-Yves Mabrut, Vincent Leroy, Georges-Philippe Pageaux, Rodolphe Anty, Sylvie Thevenon, Sinafa Si Ahmed, Aaron Hamilton, Marintha Heil, Caroline Scholtes, Massimo Levrero, Barbara Testoni, Fabien Zoulim, ECOGREFFE Study Grp
Summary: This study found that viral recurrence can occur rapidly after liver transplantation, despite prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (HBIG). The majority of patients had at least one HBV marker detected in either serum or the liver 12 months after transplantation. Optimal patient compliance to antiviral prophylaxis is crucial to prevent viral rebound.
Article
Pharmacology & Pharmacy
Thierry Verbinnen, Willem Talloen, Harry L. A. Janssen, Fabien Zoulim, Umesh Shukla, Joris J. Vandenbossche, Michael Biermer, Sandra De Meyer, Oliver Lenz
Summary: The study investigates the viral mutations in patients with hepatitis B virus infection treated with JNJ-56136379. The results demonstrate that viral breakthroughs and emergence of drug-resistant variants occurred during JNJ-56136379 monotherapy. However, the addition of nucleos(t)ide analogue treatment effectively controlled the viral mutations. This suggests that JNJ-56136379 monotherapy may not be suitable for patients with hepatitis B.
ANTIVIRAL RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Marleen van Dijk, Anders Boyd, Sylvia M. Brakenhoff, Cas J. Isfordink, Rosan A. van Zoest, Mark D. Verhagen, Robert J. de Knegt, Joost P. H. Drenth, Marc van Der Valk
Summary: Lost to follow-up (LTFU) poses a higher risk of mortality for individuals with HCV, and in the Netherlands, those who are incarcerated/institutionalized, have low income, and have psychiatric comorbidities are more likely to become LTFU.
LIVER INTERNATIONAL
(2023)
Article
Anesthesiology
Peter Kliem, Sebastian Ebel, Robert Werdehausen, Felix Girrbach, Denis Boesemann, Florian van Boemmel, Timm Denecke, Sebastian Stehr, Manuel F. Struck
Summary: Percutaneous hepatic melphalan perfusion (PHMP) is a last-line treatment for inoperable liver tumors. It selectively perfuses and saturates the liver with the chemotherapeutic agent melphalan while avoiding cytotoxic effects on the rest of the body. The procedure involves extracorporeal circulation and filtration of venous hepatic blood. Circulatory depression and coagulopathy are common during the procedure. This article reviews the anesthesiological and postprocedural management of patients undergoing PHMP, considering the challenges and special circumstances.